BioSpace News Archive

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming podium presentation on DSUVIA

In light of the corona pandemic, the Annual General Meeting 2021 of RaySearch Laboratories AB was held only through postal voting in accordance with temporary legislation.

Castlight Health, Inc., a leader in healthcare navigation, announced that senior management will participate in the William Blair 41st Annual Growth Stock Conference, including one-on-one meetings and a presentation on Thursday, June 3, 2021 at 3:00 pm ET.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at Washington University School of Medicine in St. Louis have dosed the first patient in an investigator-sponsored trial (IST) evaluating uproleselan as a prophylactic agent to reduce gastrointestinal (GI) toxicities associated with high-dose melphalan in cell transplantation

Issued patent recognizes CIRCULOGENE’s novel method of enriching cfDNA without DNA isolation, extraction or purification, enabling “in situ” genetic manipulation of biofluid samples

As one of the most important global bio-health conventions, BIO KOREA 2021 International Convention has garnered great attention from home and abroad.

Veracyte, Inc ., (Nasdaq: VCYT) announced today new data that show the company’s Afirma Xpression Atlas (XA) can identify clinically relevant gene fusions in thyroid nodule samples collected via fine needle aspiration (FNA). The findings, which will be presented June 4 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Cortexyme, Inc., a company advancing a pivotal trial in Alzheimer’s disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer and chief financial officer, will participate at the following virtual investor conferences in June 2021

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference